Evidence map›Paper›PMID 37897709›Full record

ArticleCancer2024

A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.

Vinod Pullarkat, Lisa S Chen, Joycelynne Palmer, Jianying Zhang, Timothy W Synold, Ralf Buettner, Le Xuan Truong Nguyen, Guido Marcucci, Ni-Chun Tsai, Yan Wang and 3 more

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Vinod PullarkatDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Lisa S ChenDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Joycelynne PalmerDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Jianying ZhangDivision of Biostatistics, City of Hope National Medical Center, Duarte, California, USA.
Timothy W SynoldBeckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Ralf BuettnerBeckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Le Xuan Truong NguyenDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Guido MarcucciDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Ni-Chun TsaiDivision of Biostatistics, City of Hope National Medical Center, Duarte, California, USA.
Yan WangDivision of Biostatistics, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0002-3345-600X
James O'HearnDepartment of Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0002-7287-2604
Varsha GandhiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Steven T RosenDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
City Of Hope National Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid LeukemiaR01CA201496 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ROSEN, STEVEN TERRY · 2016 to 2020
$2.3M
NCI NIH HHS CA16672NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA201496NIH HHS P30CA033572NIH HHS R01CA201496
6 · The paper itself

Abstract

backgroundThis study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 8-chloro-adenosine (8-Cl-Ado) in patients with relapsed/refractory acute myeloid leukemia (AML).

methods8-Cl-Ado was administered daily for 5 days; the starting dose was 100 mg/m

resultsThe predominant nonhematologic toxicity was cardiac with grade ≥3 toxicity. Plasma PK in all patients suggested heterogeneity among patients, yet, some dose-dependency for the accumulation of 8-Cl-Ado. Two 8-Cl-Ado metabolites accumulated at similar levels to 8-Cl-Ado. Cellular PK in eight patients indicated accumulation of 8-Cl-ATP, which was associated with AML blast cytoreduction in peripheral blood. The authors determined the RP2D of 8-Cl-Ado to be 400 mg/m

conclusionsGiven the cardiac adverse events observed, patients require monitoring for arrhythmias and QT interval during infusion. Although peripheral blood cytoreduction was observed, responses were transient, suggesting combination strategies will be required.

Indexed as

2-ChloroadenosineLeukemia, Myeloid, AcuteHumans2-Chloroadenosine8-chloroadenosine8-chloro-adenosine8-Cl-ATPAMLnucleoside analogphase 1

Identifiers

PMID37897709
PMCPMC11687610
OpenAlexW4388007063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.